论文部分内容阅读
目的:探讨重组人生长激素治疗生长激素缺乏症的临床效果及对甲状腺功能的影响。方法:选取杭州市大江东医院2016年6月至2018年6月收治的生长激素缺乏症患儿81例为研究对象，均给予重组人生长激素于患儿每晚睡前皮下注射1次，疗程为6个月。比较治疗前、治疗3个月和治疗6个月生长发育情况、骨代谢水平和甲状腺功能变化。结果:治疗3个月身高(131.76±2.28)cm和生长速率(10.40±0.87)cm/年，治疗6个月身高(134.83)cm和生长速率(11.74±0.72)cm/年，高于治疗前身高(127.32±3.49)cm和生长速率(4.32±1.08)cm/年(n F＝7.973、n P＝0.000，n F＝12.314、n P＝0.000)，且治疗6个月高于治疗3个月(身高：n t＝9.586、16.405，生长速率：n t＝39.457、51.448，均n P＝0.000)；而治疗前体质量指数(BMI)(17.21±4.28)kg/mn 2、治疗3个月(17.86±5.14)kg/mn 2和治疗6个月(18.01±4.35)kg/mn 2比较，差异无统计学意义(n F＝0.762，n P＝0.391)。治疗3个月血清骨钙素(7.19±0.38)μg/L、碱性磷酸酶(129.34±8.97)U/L水平和治疗6个月血清BGP(7.94±0.63)ng/mL、ALP(154.67±10.42)U/L，高于治疗前血清BGP(6.38±0.57)ng/mL和ALP(108.49±6.51)U/L(n F＝8.971，n P＝0.000，n F＝15.427，n P＝0.000)，且治疗6个月高于治疗3个月(n t＝9.175，n P＝0.000，n t＝16.581，n P＝0.000)。治疗前、治疗3个月和治疗6个月血清FT3、TSH和FT4水平比较，差异无统计学意义(n F＝0.893，n P＝0.287，n F＝0.472，n P＝0.517，n F＝1.084，n P＝0213)。n 结论:重组人生长激素对生长激素缺乏症患儿临床效果显著，且对甲状腺功能无明显影响，值得临床借鉴。“,”Objective:To investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency and its effect on thyroid function.Methods:From June 2016 to June 2018, 81 children with growth hormone deficiency in Da Jiangdong Hospital of Hangzhou were selected.The rhGH was given 1 time before bedtime, and the treatment course was 6 months.The growth and development, bone metabolism and thyroid function were compared before treatment, 3 months and 6 months after treatment.Results:The height and growth rate at 3 months after treatment [(131.76±2.28)cm, (10.40±0.87)cm/year] and at 6 months after treatment [(134.83)cm, (11.74±0.72)cm/year] were higher than those before treatment [(127.32±3.49)cm, (4.32±1.08)cm/year] (n F=7.973, n P=0.000, n F=12.314, n P=0.000), which at 6 months after treatment were higher than those 3 months after treatment (height: n t=9.586, 16.405, growth rate: n t=39.457, 51.448, n P=0.000). There was no statistically significant difference in BMI among before treatment [(17.21±4.28)kg/mn 2], 3 months after treatment [(17.86±5.14)kg/mn 2] and 6 months after treatment [(18.01±4.35)kg/mn 2] (n F=0.762, n P=0.391). The serum levels of BGP and ALP at 3 months after treatment [(7.19±0.38)ng/mL, (129.34±8.97)U/L] and at 6 months after treatment [(7.94±0.63)ng/mL, (154.67±10.42)U/L] were higher than those before treatment [(6.38±0.57)ng/mL, (108.49±6.51)U/L] (n F=8.971, n P=0.000, n F=15.427, n P=0.000), and the levels of BGP and ALP at 6 months after treatment were higher than those 3 months after treatment (n t=9.175, n P=0.000, n t=16.581, n P=0.000). There were no statistically significant differences in serum FT3, TSH and FT4 levels before treatment, 3 months after treatment and 6 months after treatment (n F=0.893, n P=0.287, n F=0.472, n P=0.517, n F=1.084, n P=0213).n Conclusion:rhGH has significant clinical effects on children with growth hormone deficiency, and has no significant effect on thyroid function, which is worthy of clinical reference.